The global extracorporeal membrane oxygenation (ECMO) devices market is expected to experience significant growth over the next few years, driven by increasing investment in healthcare infrastructure, growing awareness of ECMO therapy, and the rising adoption of ECMO devices in emerging markets. The market is also likely to be driven by the ongoing COVID-19 pandemic, which has highlighted the need for advanced life support systems to treat critically ill patients with severe respiratory failure, says GlobalData, a leading data and analytics company.

According to GlobalData, the top revenue grossing sub-segments for ECMO include blood pumps, integrated units, and oxygenators, which together account for approximately 80% of the total market revenue in 2022.

Getinge AB is a market leader, that is leading in integrated units, which is a second largest sub-segment overall. Getinge AB is leading in every region except the Northeast region.

Kamilla Kan, Medical Analyst at GlobalData, a leading data and analytics company, comments: “The ECMO market is thriving with increasing prevalence of respiratory and cardiac failure, and technological advancements in ECMO devices such as improved portability, increased automation, and enhanced monitoring capabilities. The market is characterized by intense competition, with companies focusing on product development, strategic collaborations, and mergers and acquisitions to gain a competitive edge.

“As the market continues to evolve, ECMO will likely become an increasingly important part of the healthcare landscape, providing life-saving treatment options for critically ill patients.”